RxDoctor Payments DataLook up a doctor →

Craig Walker, MD

Interventional Cardiology · Houma, LANPI 1548267529

Payments from drug & device makers

$5,530,320in general payments, 2019–2025

Across 1,534 payments — averaging $3605.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$2.5M
  • Anika Therapeutics, Inc.$920K
  • Cardiva Medical, Inc.$694K
  • Johnson & Johnson$310K
  • Philips North America LLC$254K
  • Boston Scientific$95K
  • plus $764K from 54 others
$27,790in research payments, 2019–2025

Across 6 payments — averaging $4631.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$18K
  • Veryan Medical Incorporated$10K

What the payments were for

  • Consulting fees$129,5543%
  • Speaking & faculty fees$719,54014%
  • Travel & lodging$75,2962%
  • Food & beverage$50,9291%
  • Education$650%
  • Gifts$990%
  • Ownership interest$812,21416%
  • Other$3,223,06264%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bard Peripheral Vascular, Inc.35$2,493,090
Anika Therapeutics, Inc.4$920,023
Cardiva Medical, Inc.60$694,017
Johnson & Johnson222$309,761
Philips North America LLC253$254,082
Boston Scientific103$94,609
Abbott92$93,274
Novartis23$74,952
Boehringer Ingelheim62$74,374
Novo Nordisk47$57,379
Vasorum USA Inc.7$50,241
Amgen76$43,500
Trireme Medical LLC3$36,700
Bayer19$34,670
Asahi Intecc USA, Inc.53$31,691
Centerline Biomedical Inc.5$26,174
Idev Technologies, Inc.1$25,355
Medalliance LLC6$25,075
Cordis US CORP.30$24,809
Angiodynamics, Inc.47$21,617
Esperion Therapeutics, Inc.15$20,574
Intact Vascular, Inc.1$16,360
Contego Medical, Inc7$12,776
Veryan Medical Incorporated19$12,388
Lilly USA, LLC7$12,317
GE HealthCare15$11,030
Shockwave Medical, Inc14$9,593
Biotronik Inc.29$8,301
M.a. Med Alliance S.A.9$6,508
W. L. Gore & Associates, Inc.9$6,497
Actelion Pharmaceuticals, Ltd6$4,598
Asahi Intecc CO., LTD.10$3,005
Cardiovascular Systems Inc.22$2,924
Terumo Medical Corporation9$2,890
Penumbra, Inc.10$2,252
Avantec Vascular Corporation6$1,608
Janssen Scientific Affairs, LLC3$1,583
Medtronic(2 entities)28$1,192
Corindus Inc.9$987
Reflow Medical Inc10$844
Cook Medical LLC14$716
Itamar Medical Inc3$676
Tactile Systems Technology Inc12$622
Siemens Medical Solutions USA, Inc.5$506
Regeneron Healthcare Solutions, Inc.4$311
Endologix LLC3$309
Recor Medical Inc3$303
Surmodics, Inc.4$296
Pfizer20$290
Abiomed34$268
Celonova Biosciences, Inc.1$261
Nipro Medical Corporation3$239
Venclose Inc.4$231
Irhythm Technologies, Inc.1$158
Imperative Care, Inc1$143
Venturemed Group, Inc.1$136
ZOLL Respicardia, Inc.1$124
Mercator Medsystems, Inc.2$123
ZOLL Medical Corporation1$114
Biocompatibles, Inc.1$111

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,530,320 in reported general payments places this provider in the 95th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$360,926
Medicare patients
409
Services billed
4,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin191$202,080
EliquisApixaban148$177,513
XareltoRivaroxaban175$160,702
Repatha SureclickEvolocumab176$119,397
MounjaroTirzepatide54$61,045
OzempicSemaglutide29$47,366
Praluent PenAlirocumab49$25,611
KerendiaFinerenone22$23,533
BrilintaTicagrelor25$19,354
EntrestoSacubitril/Valsartan12$13,325
VascepaIcosapent Ethyl18$10,211
Repatha PushtronexEvolocumab17$9,958
FarxigaDapagliflozin Propanediol11$8,880
ClopidogrelClopidogrel Bisulfate896$8,554
Prasugrel Hcl71$6,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$74,374$202,080191 claims
PfizerEliquis$290$177,513148 claims
Johnson & JohnsonXarelto$309,761$160,702175 claims
Lilly USA, LLCMounjaro$12,317$61,04554 claims
Novo NordiskOzempic$57,379$47,36629 claims
BayerKerendia$34,670$23,53322 claims
NovartisEntresto$74,952$13,32512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Houma

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →